

# Annual Review of Muscle Relaxants - Fiscal Year 2011

## Oklahoma HealthCare Authority

### April 2012

#### Current Prior Authorization Criteria

---

##### The following criteria are recommended for approval of a Tier-2 product:

1. Failure with at least two Tier-1 medications within the past 90 days defined as no beneficial response after at least two weeks of use during which time the drug has been titrated to the recommended dose.
2. Approvals will be for the duration of three months, except for members with chronic diseases such as multiple sclerosis, cerebral palsy, muscular dystrophy, paralysis, or other chronic musculoskeletal diagnosis confirmed with diagnostic results, in which case authorizations will be for the duration of one year.
3. For repeat authorizations, there must be documentation of failed withdrawal attempt within past three months defined as increase in pain and debilitating symptoms when medication was discontinued.

**The following criteria are recommended for approval of carisoprodol 350mg or carisoprodol 350mg combination products:** A cumulative 90 therapy day window per 365 days will be in place for these products, further approval will be based on the following:

1. An additional approval for 1 month will be granted to allow titration or change to a Tier1 muscle relaxant. Further authorizations will not be granted.
2. Clinical exceptions may be made for members with the following diagnosis and approvals will be granted for the duration of one year: multiple sclerosis, cerebral palsy, muscular dystrophy, or paralysis.

##### **Carisoprodol (Soma®) 250mg:**

3. Must provide detailed documentation regarding member's inability to use other skeletal muscle relaxants including carisoprodol 350mg, and specific reason member cannot be drowsy for even a short time period. Member must not have other sedating medications in current claims history.
4. A diagnosis of acute musculoskeletal pain, in which case, the approval will be for 14 days per 365 day period. Conditions requiring chronic use will not be approved.

**Zanaflex capsules:** Tizanidine tablets must be tried prior to consideration of the capsules. The capsules may be considered for approval only if there is supporting information as to why the member cannot take the tablets.

**Amrix® and Fexmid®:** Approval is based on clinical documentation of inability to take other generically available forms of cyclobenzaprine tabs.


Skeletal Muscle Relaxants		
Tier-1	Tier-2	Hard PA
Cyclobenzaprine (Flexeril <sup>®</sup> ) Baclofen (Lioresal <sup>®</sup> ) Tizanidine (Zanaflex <sup>®</sup> ) Methocarbamol (Robaxin <sup>®</sup> ) Chlorzoxazone (Parafon Forte <sup>®</sup> ) Orphenadrine (Norflex <sup>®</sup> )	Metaxalone (Skelaxin <sup>®</sup> )	Carisoprodol (Soma <sup>®</sup> ) 350mg Carisoprodol w Aspirin Carisoprodol, ASA, Codeine Carisoprodol (Soma <sup>®</sup> ) 250mg Tizanidine (Zanaflex <sup>®</sup> ) Caps Cyclobenzaprine ER (Amrix <sup>®</sup> ) Caps Cyclobenzaprine 7.5mg (Fexmid <sup>®</sup> ) Tabs

### Utilization of Muscle Relaxants


#### Comparison of Fiscal Years

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2010	31,725	86,819	\$1,059,064.58	\$12.20	\$0.53	8,757,881	2,015,588
2011	36,415	101,690	\$1,055,640.03	\$10.38	\$0.45	8,051,082	2,355,332
% Change	14.80%	17.10%	-0.30%	-14.90%	-15.10%	-8.10%	16.90%
Change	4,690	14,871	-\$3,424.55	-\$1.82	-\$0.08	-706,799	339,744

#### Demographics of Members Utilizing Muscle Relaxants: FY 2011



### Prescribers of Muscle Relaxants by Number of Claims: FY 2011




---

### Prior Authorization of Muscle Relaxants

There were a total of 1,874 petitions submitted for this PBPA category during fiscal year 2011. The following chart shows the status of the submitted petitions.

### Status of Petitions for Muscle Relaxant Medications: FY 2011



---

### Market News and Updates

#### Upcoming Patent Expirations :

- Zanaflex® (tizanidine) capsules- November 2021
- Amrix® (cyclobenzaprine extended-release)- February 2025

---

### Conclusion and Recommendations

The College of Pharmacy does not recommend any changes to this category at this time.

### Utilization Details of Muscle Relaxants: Fiscal Year 2011

BRAND NAME	CLAIMS	UNITS	DAYS	MEMBERS	COST	UNITS/ DAY	CLAIMS/ MEMBER	COST/ DAY	PERCENT COST
CYCLOBENZAPR TAB 10MG	44,878	2,292,997	943,716	21,495	\$346,418.92	2.43	2.09	\$0.37	32.82%
CARISOPRODOL TAB 350MG	12,901	894,372	328,297	5,762	\$111,752.24	2.72	2.24	\$0.34	10.59%
TIZANIDINE TAB 4MG	11,973	985,692	314,276	3,816	\$123,993.58	3.14	3.14	\$0.39	11.75%
BACLOFEN TAB 10MG	8,974	837,950	254,264	2,326	\$72,205.94	3.3	3.86	\$0.28	6.84%
CYCLOBENZAPR TAB 5MG	6,231	250,282	106,866	3,928	\$42,717.02	2.34	1.59	\$0.40	4.05%
BACLOFEN TAB 20MG	3,966	1,907,037	115,021	798	\$62,403.38	16.58	4.97	\$0.54	5.91%
METHOCARBAM TAB 750MG	3,890	308,931	87,047	1,852	\$40,628.41	3.55	2.1	\$0.47	3.85%
METHOCARBAM TAB 500MG	2,740	194,811	58,425	1,418	\$27,096.11	3.33	1.93	\$0.46	2.57%
ORPHENADRINE TAB 100MG ER	2,385	104,855	52,788	1,325	\$54,856.44	1.99	1.8	\$1.04	5.20%
TIZANIDINE TAB 2MG	1,503	113,104	40,610	522	\$15,317.27	2.79	2.88	\$0.38	1.45%
CHLORZOXAZON TAB 500MG	1,398	91,241	32,250	672	\$9,357.35	2.83	2.08	\$0.29	0.89%
METAXALONE TAB 800MG	519	40,034	14,102	187	\$121,823.78	2.84	2.78	\$8.64	11.54%
BACLOFEN POW	124	19,284	3,507	22	\$1,534.12	5.5	5.64	\$0.44	0.15%
ORPHEN CPD TAB DS	77	4,234	1,392	44	\$7,543.13	3.04	1.75	\$5.42	0.71%
ORPH/ASA/CAF TAB	34	1,842	574	16	\$2,433.29	3.21	2.13	\$4.24	0.23%
CARISOPR/ASA TAB 200-325	19	1,018	306	11	\$1,682.92	3.33	1.73	\$5.50	0.16%
SKELAXIN TAB 800MG	17	1,230	510	5	\$3,394.91	2.41	3.4	\$6.66	0.32%
CARISOPRODOL TAB ASA/COD	16	586	259	6	\$709.91	2.26	2.67	\$2.74	0.07%
AMRIX CAP 15MG	15	435	435	6	\$4,376.92	1	2.5	\$10.06	0.41%
AMRIX CAP 30MG	9	270	270	2	\$2,682.07	1	4.5	\$9.93	0.25%
CARISOPRODOL TAB 250MG	6	420	135	5	\$1,179.59	3.11	1.2	\$8.74	0.11%
ZANAFLEX CAP 6MG	6	180	160	1	\$766.61	1.13	6	\$4.79	0.07%
SOMA TAB 250MG	3	101	39	3	\$318.86	2.59	1	\$8.18	0.03%
ORPHENADRINE INJ 30MG/ML	3	6	3	3	\$26.70	2	1	\$8.90	0.00%
CYCLOBENZAPR CAP 15MG ER	1	20	20	1	\$203.91	1	1	\$10.20	0.02%
ZANAFLEX CAP 2MG	1	90	30	1	\$186.04	3	1	\$6.20	0.02%
CYCLOBENZAPR POW HCL	1	61	30	1	\$30.61	2.02	1	\$1.02	0.00%
<b>TOTALS:</b>	<b>101,690</b>	<b>8,051,083</b>	<b>2,355,332</b>	<b>36,415*</b>	<b>\$1,055,640.03</b>	<b>3.42</b>	<b>2.79</b>	<b>\$0.45</b>	<b>100.00%</b>

*\*Total number of unduplicated members*